Ann S LaCasce
Overview
Explore the profile of Ann S LaCasce including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
4826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lurain K, El Zarif T, Ramaswami R, Nassar A, Adib E, Abdel-Wahab N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 May;
24(8):523-530.
PMID: 38714474
Background: Despite a higher risk of classical Hodgkin lymphoma (cHL) in people with HIV and the demonstrated safety and efficacy of PD-1 blockade in cHL, there are limited data on...
12.
Driessen J, de Wit F, Herrera A, Zinzani P, LaCasce A, Cole P, et al.
Blood Adv
. 2024 Mar;
8(11):2740-2752.
PMID: 38502227
Several single-arm studies have explored the inclusion of brentuximab vedotin (BV) in salvage chemotherapy followed by autologous stem cell transplantation (ASCT) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, no...
13.
Ryan C, Armand P, LaCasce A
Blood
. 2024 Mar;
145(7):663-672.
PMID: 38498174
Despite many recent therapeutic advances, mantle cell lymphoma (MCL) remains a largely incurable disease. Treatments for patients with relapsed/refractory (R/R) disease are limited in number and in response durability. Therefore,...
14.
Nemec R, Scherrer-Crosbie M, Abramson J, Redd R, Gilman H, Ho T, et al.
Leuk Lymphoma
. 2024 Feb;
65(6):783-788.
PMID: 38380861
STOP-CA was a multicenter, double-blind, randomized, placebo-controlled trial comparing atorvastatin to placebo in treatment-naïve lymphoma patients receiving anthracycline-based chemotherapy. We performed a preplanned subgroup to analyze the impact of atorvastatin...
15.
Ahn I, Brander D, Ren Y, Zhou Y, Tyekucheva S, Walker H, et al.
Blood Adv
. 2024 Jan;
8(4):832-841.
PMID: 38163317
We previously reported high rates of undetectable minimal residual disease <10-4 (uMRD4) with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) followed by 2-year ibrutinib maintenance (I-M) in treatment-naïve chronic lymphocytic...
16.
Mehrtash A, Ziegler E, Idris T, Somarouthu B, Urban T, LaCasce A, et al.
Comput Med Imaging Graph
. 2023 Dec;
111:102312.
PMID: 38141568
Accurate lymph node size estimation is critical for staging cancer patients, initial therapeutic management, and assessing response to therapy. Current standard practice for quantifying lymph node size is based on...
17.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, et al.
J Natl Compr Canc Netw
. 2023 Nov;
21(11):1118-1131.
PMID: 37935098
Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the...
18.
Merryman R, Redd R, Freedman A, Ahn I, Brown J, Crombie J, et al.
Ann Hematol
. 2023 Oct;
103(1):185-198.
PMID: 37851072
Antibodies targeting PD-1 or 4-1BB achieve objective responses in follicular lymphoma (FL), but only in a minority of patients. We hypothesized that targeting multiple immune receptors could overcome immune resistance...
19.
Crosswell H, LaCasce A, Bartlett N, Straus D, Savage K, Zinzani P, et al.
Haematologica
. 2023 Oct;
109(3):982-987.
PMID: 37794803
No abstract available.
20.
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial
Neilan T, Quinaglia T, Onoue T, Mahmood S, Drobni Z, Gilman H, et al.
JAMA
. 2023 Aug;
330(6):528-536.
PMID: 37552303
Importance: Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use of atorvastatin may be associated with a reduction in cardiac dysfunction due to...